VITAS Net Revenue: $391.4 million, an increase of 17.3% year-over-year. VITAS Admissions: 16,775, a 6.3% increase from the prior year. Average Daily Census (ADC) for VITAS: 21,785 patients, a 15.5% ...
Chemed’s CHE Roto-Rooter business has been registering robust performance over the past few quarters. A good solvency position buoys optimism. The company currently carries a Zacks Rank #2 (Buy). Over ...
Hosted on MSN
Chemed outlines 2025 growth strategies amid strong VITAS momentum and Roto-Rooter recovery
Kevin McNamara, CEO of Chemed, highlighted robust performance in VITAS operations, with a 7.3% year-over-year increase in admissions to 18,139 and a 13.1% growth in average daily census (ADC) to ...
VITAS Net Revenue: $407.7 million in Q3 2025, a 4.2% increase from the prior year. Roto-Rooter Revenue Increase: 1.1% in Q3 2025 compared to Q3 2024. VITAS Adjusted EBITDA: $70.4 million, a 3.8% ...
Hosted on MSN
CHE Q1 Earnings Call: Acquisition-Driven Growth and Medicare Cap Strategy Shape Outlook
Healthcare services company Chemed Corporation (NYSE:CHE) in Q1 CY2025, with sales up 9.8% year on year to $646.9 million. Its non-GAAP profit of $5.63 per share was 1.5% above analysts’ consensus ...
Chemed Corporation CHE reported adjusted earnings per share (EPS) of $5.32 in the third quarter of 2023, up 24.9% year over year. The figure also surpassed the Zacks Consensus Estimate by 8.1%. The ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Chemed Corporation’s recent earnings call ...
On Aug 11, we issued an updated research report on Chemed Corporation CHE. The company currently operates two wholly-owned subsidiaries — VITAS Healthcare and Roto-Rooter. Over the past six months, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback